Risperdal Settlement Shows False Claims Act Prosecutions Still Have Teeth After Caronia
This article was originally published in RPM Report
Executive Summary
A $2.2 billion settlement prompts another round of headlines about the pharmaceutical industry's marketing practices -- and no apparent indication that the Caronia ruling is changing the way prosecutors (and the public) perceive off-label promotion.